Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC) ; volume:14 ; number:1 ; day:25 ; month:7 ; year:2014 ; pages:1-8 ; date:12.2014
BMC urology ; 14, Heft 1 (25.7.2014), 1-8, 12.2014
- Urheber
-
Gupta, Eva
- Beteiligte Personen und Organisationen
-
Guthrie, Troy
Tan, Winston
SpringerLink (Online service)
- DOI
-
10.1186/1471-2490-14-55
- URN
-
urn:nbn:de:1111-2016071626034
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gupta, Eva
- Guthrie, Troy
- Tan, Winston
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ureter metastatic castration-resistant prostate cancer: a case report
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Ureter metastatic castration-resistant prostate cancer: a case report
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Ureter metastatic castration-resistant prostate cancer: a case report
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
The changing landscape of hormonal therapy in castration-resistant prostate cancer
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer